PD‐1/PD‐L1 monoclonal antibodies relieved the inhibitory effects of the PD‐1/PD‐L1 signaling pathway on CD8+ T cells, restoring their ability to kill tumor cells. This evidence concerns the gene CD8A and neoplasm.